Navigation Links
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Date:10/17/2007

SOUTH SAN FRANCISCO, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that its lead product candidate, picoplatin, has been granted orphan medicinal product designation for the treatment of small cell lung cancer (SCLC) by the European Commission. This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA).

Picoplatin is currently being studied in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is evaluating overall survival as the primary endpoint and is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.

"The receipt of orphan drug designation in the EU for picoplatin for the treatment of small cell lung cancer is an important achievement and builds on our success of obtaining orphan drug designation for picoplatin in the U.S.," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "Because many SCLC patients who are treated with platinum therapies relapse quickly or do not respond at all, new therapies that are active in this disease and that can overcome platinum resistance are urgently needed. We are committed to bringing picoplatin to market in the U.S. and the EU for this severely underserved patient population and are making significant progress in enrolling patients in our pivotal SPEAR trial for this indication."

About Orphan Drug Designation in the European Union

The EU orphan medicinal product designation aims to encourage the development of drugs involved in the diagnosis, prevention or treatment of a life-threatening or chr
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 The Pittcon Organizing Committee is ... Food Safety Tech , an e-Journal and producer of ... for the second year for the co-location of Food Labs ... partnership provides that the registration fee to attend the two-day ...
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Md., Sept. 13 Total Site Solutions,(TSS), a ... who provides,comprehensive services for the planning, design and ... in the,pharmaceutical and biotech industry has awarded them ... Project. TSS originally performed technology consulting services ...
... Sept. 13 Southern Research,Institute today announced that ... as SR9025, to Virium Pharmaceuticals, Inc. To date, ... approval and are on,the market. Six others, including ... early clinical trials. (Photo: http://www.newscom.com/cgi-bin/prnh/20070913/DCTH022 ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
Cached Biology Technology:Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 3Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals 2Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2
(Date:4/20/2014)... 2014 -- Using corn crop residue to make ethanol ... more greenhouse gases than gasoline, according to a study ... . , The findings by a University of Nebraska-Lincoln ... can be used to meet federal mandates to ramp ... Corn stover -- the stalks, leaves and cobs in ...
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
(Date:4/18/2014)... they,re planted may be good news for a garden. But ... a plant whose seeds sprouted at the first ,warm spell ... insurance policy against late frosts or unexpected dry spells, it ... Plants whose seeds put off sprouting until conditions are more ... of researchers working at the National Evolutionary Synthesis Center in ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Plants with dormant seeds give rise to more species 2
... time in the developing mind, Daniel Casasanto of the ... and colleagues at the Aristotle University of Thessaloniki and ... along parallel paths for different distances or durations. The ... each race, reporting which animal went for a longer ...
... executed two license agreements with SuperPower, a wholly-owned ... the intellectual property on second generation (2G) high ... the Sponsored Research Agreement (SRA) previously executed between ... led by Venkat Selvamanickam, M.D. Anderson chair professor ...
... March 31, 2010 Mariam El-Ashmawy, a student ... Training Program, has been awarded a 2010 Gilliam Fellowship ... (HHMI). Ms. El-Ashmawy, a Lewisville native, is one ... selected this year from institutions across the country. Each ...
Cached Biology News:Children use space to think about time 2SuperPower and UH sign high temperature superconducting wire license agreements 2UT Southwestern student receives fellowship from Howard Hughes Medical Institute 2